title: Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy.
abstract: The role of adjuvant chemoradiation therapy (CT/XRT) in the treatment of cholangiocarcinoma is controversial. We undertook this study to determine whether CT/XRT is appropriate after resection of cholangiocarcinomas. One hundred ninety-two patients with cholangiocarcinomas were treated from 1988 to 1999. After resection, patients were assigned a stage (TNM) and were stratified by location of the tumor as intrahepatic, perihilar, and distal tumors. Data are presented as mean +/- standard deviation. Of 192 patients 92 (48%) underwent resections of cholangiocarcinomas. Thirty-four patients had liver resections, 25 had bile duct resections, and 33 underwent pancreaticoduodenectomies. Thirty-four patients had adjuvant CT/XRT, three had adjuvant chemotherapy, four had neoadjuvant CT/XRT, and 50 had no radiation or chemotherapy. Mean survival of resected patients with adjuvant CT/XRT was 42 +/- 37.0 months and without CT/XRT it was 29 24.5 months (P = 0.07). Mean survival of patients with distal tumors receiving or not receiving CT/XRT was 41 +/- 21.8 versus 25 +/- 20.1 months, respectively, (P = 0.04). Adjuvant chemoradiation improves survival after resection for cholangiocarcinoma (P = 0.07) particularly in patients undergoing resection for distal tumors (P = 0.04). Benefits of adjuvant CT/XRT are apparent when stratified by location of cholangiocarcinomas rather than staging.
authors.affiliation: Department of Surgery, University of South Florida, Tampa 33601, USA.
authors.forename: F M
authors.initials: FM
authors.lastname: Serafini
authors.forename: D
authors.initials: D
authors.lastname: Sachs
authors.forename: M
authors.initials: M
authors.lastname: Bloomston
authors.forename: L C
authors.initials: LC
authors.lastname: Carey
authors.forename: R C
authors.initials: RC
authors.lastname: Karl
authors.forename: M M
authors.initials: MM
authors.lastname: Murr
authors.forename: A S
authors.initials: AS
authors.lastname: Rosemurgy
mesh_terms: D000368:Aged; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D001652:Bile Ducts / Q000601:surgery; D001653:Bile Ducts, Intrahepatic; D017024:Chemotherapy, Adjuvant; D018281:Cholangiocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D016577:Pancreaticoduodenectomy; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate